JapicCTI‐194920.

Study name	A comparison study on WP‐1303 and ripasudil ophthalmic solution in patients with primary open‐angle glaucoma (POAG) or ocular hypertension (OH)
Methods	Study type: interventional  Study design: multicenter, randomized, single‐masked, parallel‐group
Participants	Inclusion criteria: men and women with POAG or OHT; IOP < 35 mmHg for both eyes; 1 eye is ≥ 21 mmHg; aged > 20 years Exclusion criteria: visual acuity < 0.3; presence of active eye disease (e.g. uveitis, ocular infection, severe dry eye); pregnant or lactating women or women who desire to be pregnant; people judged inappropriate to participate in the study by investigator or subinvestigator
Interventions	WP‐1303 Ripasudil hydrochloride hydrate
Outcomes	Primary outcomes Efficacy: IOP Safety: adverse event and adverse drug reaction Secondary outcome Efficacy: IOP
Starting date	6 September 2019
Contact information	Wakamoto Pharmaceutical Co., Ltd. Clinical Development. Address: 2‐2, Nihonnbashi Honcho 2‐chome, Chuo‐ku Tokyo. Telephone: +81‐3‐3279‐0370
Notes	Study terminated on 25 December 2019.